1,25(OH) 2D3 在体外和体内促进胰岛素的分泌,通过经典的热致死途径
Yuxuan Zheng1, Zhihao Wu1, Xun Wei2
1Laboratory Animal Center of Suzhou Medical College, Soochow University, Suzhou, China.
Biochemical and biophysical research communications
|December 6, 2024
概括
1,25(OH) 2D3,一种维生素D的形式,通过抑制热致死,减少炎症并通过抑制2型糖尿病的胰腺细胞保护胰腺细胞. 这一发现表明,维生素D可以通过向这种细胞死亡途径来帮助控制糖尿病.
科学领域:
- 内分泌学 在内分泌学.
- 免疫学 免疫学 免疫学
- 细胞生物学 细胞生物学
背景情况:
- 糖尿病是一种与炎症相关的慢性代谢障碍.
- 已知维生素D与2型糖尿病的关联,但其抗炎机制尚不清楚.
- 炎症性细胞死亡的Pyroptosis与糖尿病的发病有关.
研究的目的:
- 为了研究火灭菌在糖尿病中的胰腺β细胞功能障碍中的作用.
- 为了探索1,25(OH) 2D3 (维生素D) 如何通过热死途径影响2型糖尿病.
主要方法:
- 建立了2型糖尿病的体内和体外模型.
- 进行了1,25(OH) 2D3干预,以评估其影响.
- 测量胰岛素分泌,炎症因子和与热死相关的蛋白质表达.
主要成果:
- 1,25(OH) 2D3通过降低与热致死相关的蛋白质表达来表现出抗炎作用.
- 维生素D保护胰腺β细胞免受2型糖尿病引起的损伤,改善胰岛素分泌.
- 抑制气皮素D (GSDMD) 降低了 pyroptosis,炎症和胰腺细胞损伤.
结论:
- 通过古典途径的热致使胰腺细胞在2型糖尿病中的功能障碍.
- 1,25 (((OH) 2D3可能作为一种辅助疗法,抑制胰腺β细胞中的热致死.
- 用维生素D向火灭菌路径可以通过减少炎症来缓解糖尿病症状.
关键词:
1,25 (((OH) 2D3 3D3 3D3 3D3 3D3 3D3 3D3 3D4 3D4 3D5 3D6 3D7 3D8 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9 3D9糖尿病 糖尿病 糖尿病炎症 炎症是一种炎症.热性灭症 (Pyroptosis) 是一种相关概念视频
Insulin Secretory Vesicles
4.8K
Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion
1.1K
The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
Insulin and C-peptide are...
1.1K
Insulin: The Receptor and Signaling Pathways
1.1K
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but...
1.1K
Insulin: Biosynthesis, Chemistry, and Preparation
357
The endoplasmic reticulum (ER) of pancreatic β-cells synthesizes preproinsulin, which consists of a signal peptide, A and B chains, and a C-peptide. Preproinsulin is then cleaved and folded into proinsulin, which translocates to the Golgi apparatus for sorting and packaging into secretory granules. In these granules, enzymatic clipping generates insulin and C-peptide.
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
Damage or functional impairment of β-cells inhibits insulin production, leading to diabetes. Diabetes treatment...
357
Hormones Regulating Blood Glucose
3.1K
Insulin is released by beta cells of the pancreas when blood glucose levels are high. It facilitates glucose absorption and utilization in insulin-dependent cells with insulin receptors on their plasma membranes. Insulin promotes glucose uptake by increasing the number of glucose transport proteins in the cell membrane, allowing glucose to enter the cell. As a result, glucose utilization and ATP production are enhanced.
In addition to accelerating glucose uptake and utilization, insulin has...
In addition to accelerating glucose uptake and utilization, insulin has...
3.1K
Glucagon-like Receptor Agonists
298
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
298


